FDA approves belzutifan with pembrolizumab for adjuvant renal cell carcinoma

# FDA approves belzutifan with pembrolizumab for adjuvant renal cell carcinoma The U.S. Food and Drug Administration has approved belzutifan (Welireg) in combination with pembrolizumab (Keytruda) for adjuvant treatment of clear cell renal cell carcinoma in patients at intermediate-high or high risk of recurrence following nephrectomy. [c01] The approval is based on the Phase 3 LITESPARK-022 trial, which enrolled 1,841 patients. Merck, pembrolizumab's marketer, reported that the combination reduced the risk of recurrence, metastasis, or death by 28% versus placebo in the adjuvant setting. [c02] Disease-free survival at 24 months was 81% with the combination compared with 74% in the control arm. [c02] Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor. The pairing targets complementary pathways in renal cell carcinoma after curative-intent surgery. [c03] ## What it means Adjuvant immuno-oncology combinations have reshaped post-surgical RCC management, but options for intermediate-high-risk patients have remained contested. This label expansion gives Merck a fixed-dose adjuvant regimen pairing its PD-1 backbone with a HIF-2α agent — a combination that could extend Keytruda's commercial runway in renal cancer beyond metastatic use. *(Original synthesis grounded in c01–c03.)* Clinicians will weigh the 7-percentage-point absolute improvement in 24-month DFS against combination toxicity and monitoring burden; detailed subgroup and quality-of-life data will matter for adoption in intermediate-risk cohorts. *(Original clinical framing.)* ## What's next Merck has not yet disclosed full hazard ratios for all secondary endpoints in the public approval summary. We will update this page when peer-reviewed trial data and NCCN guideline revisions are published. [c02] --- *Sources: FDA approval announcement [c01]; LITESPARK-022 topline via sponsor release [c02]; belzutifan and pembrolizumab mechanism labels [c03].*